The Clorox Company announced executive leadership changes. Eric Reynolds, Executive Vice President – Chief Operating and Strategy Officer, provided notice of his intention to resign after 27 years with the company. He will step down from his role effective December 2, 2025.
Reynolds will be available on an advisory basis as needed through February 2, 2026. The company stated it does not expect to appoint a replacement for Mr. Reynolds.
Insider transaction summary for CLOROX CO (CLX)
On 10/03/2025 Director and Chief Executive Officer Linda J. Rendle received 43,370 shares of common stock following settlement of a 2022 performance unit grant that vested on 10/03/2025. The shares were issued at an effective price of $122.25 per share. The filing shows share withholding to satisfy tax obligations: 1,022 shares withheld for performance stock unit taxes and 8,440 shares withheld for restricted stock taxes. After these transactions and including 4,274 dividend-reinvested shares, the reporting person beneficially owned 201,990 shares (direct).
Laurene E. Peck, Vice President, Chief Accounting Officer & Corporate Controller of Clorox Co (CLX), reported changes in her beneficial ownership on 10/03/2025. She received 1,418 shares on settlement of a 2022 performance unit grant at a reported price of $122.25 per share and elected to defer settlement under the 2005 Stock Incentive Plan. The filing shows share withholding to cover tax obligations: 36 shares withheld for performance stock units and 243 shares withheld for restricted stock, both at $122.25. Following these transactions and including a 186-share dividend reinvestment, total beneficial ownership is reported as 7,271 shares (direct) before certain adjustments and 6,992 shares noted as indirect via a trust of a parent. The form is signed by an attorney-in-fact on 10/07/2025.
Insider stock settlement and tax withholdings recorded for CLOROX (CLX). On 10/03/2025 the reporting person received 6,812 common shares at $122.25 as the settlement of a 2022 performance unit award that vested and was elected for deferral under the company plan. The company withheld 162 shares and 948 shares to satisfy tax obligations for performance stock units and restricted stock, respectively. After these transactions the reported beneficial ownership declined to 35,133 shares, which includes 722 shares from dividend reinvestment.
Clorox Co. executive Stacey Grier reported receiving 9,913 shares of common stock on October 3, 2025, in settlement of a 2022 Performance Unit Grant valued at $122.25 per share, with part of the award deferred under the company’s Stock Incentive Plan. On the same date, 1,032 shares were withheld by the company to satisfy tax obligations related to vesting awards. After these transactions, Grier directly owns 32,203 shares of Clorox common stock, including 1,004 acquired through the plan’s dividend reinvestment feature.
Executive stock vesting and tax-related share withholdings: The Chief Operating Officer reported transactions on 10/03/2025 involving 15,489 shares issued upon settlement of a 2022 performance unit grant at an indicated price of $122.25 per share. The filing shows the company withheld 2,755 shares to satisfy tax obligations for restricted stock and 7,436 shares to satisfy tax obligations for performance stock units. After these transactions the reporting person beneficially owned 69,313 shares (including 739 dividend-reinvested shares).
Insider transaction summary: An executive officer of Clorox Co. (CLX) reported transactions on 10/03/2025 that settled a 2022 performance-unit grant into 9,293 shares of common stock at a per-share price of $122.25. The filing shows two share withholdings to satisfy tax obligations: 1,653 shares and 3,488 shares, each recorded at $122.25. Following these transactions the reporting person beneficially owns 38,280 shares (this total includes 534 shares from dividend reinvestment). The Form 4 was signed by an attorney-in-fact on 10/07/2025.
Insider transactions at Clorox Co (CLX): an executive reported multiple equity transactions on 10/03/2025. The reporting person acquired 8,672 shares through settlement of a 2022 performance unit grant at an effective price of $122.25, increasing direct holdings to 35,667 shares. The filing also shows withholding of 1,904 and 3,629 shares to satisfy tax obligations tied to restricted stock and performance stock units, respectively, and 462 shares from dividend reinvestment. Additionally, 612.574 shares are held indirectly via the company 401(k). The form was signed by an attorney-in-fact on 10/07/2025.
Clorox insider transaction: The company's EVP & Chief Financial Officer received 2,581 shares upon settlement of a 2022 Performance Unit Grant that vested on 10/03/2025 at a reported per-share value of $122.25. The filing shows two share-withholdings to satisfy tax obligations: 421 shares withheld for restricted stock taxes and 893 shares withheld for performance stock unit taxes. After these transactions, the reporting person beneficially owned 20,864 shares (which includes 167 dividend-reinvestment shares).
Nina Barton, EVP-Group Pres–Care & Conn at Clorox Co. (CLX), reported a sale of 622 shares of Clorox common stock on 10/03/2025 at a price of $122.25 per share. The transaction is recorded as code F and is explained as withholding of shares to satisfy tax obligations related to the vesting of restricted stock. After the transaction, Ms. Barton beneficially owns 27,895 shares, which includes 21 shares acquired via a dividend reinvestment feature of the Company’s Stock Incentive Plan.
The report was signed by an attorney-in-fact on 10/07/2025. The filing indicates a routine tax-withholding disposition rather than an open-market sale, and it shows continued significant insider ownership by an executive responsible for the company’s care and consumer connections businesses.